摘要
目的评估转移性激素敏感性前列腺癌(mHSPC)患者外周血AR-V7表达水平与雄激素剥夺治疗(ADT)后PSA动力学指标的关系。方法选取2020年6月至2021年10月在我院新诊断的mHSPC患者57例,患者通过外周血进行AR-V7检测并接受ADT治疗。根据AR-V7检测结果将样本分为AR-V7检出组和未检出组,分析治疗后3个月及6个月时的PSA下降速率(PSADR)和PSA百分比下降速率(PSAPDR)。将样本进行亚组分析,分别分析检出组和未检出组中使用阿比特龙和使用比卡鲁胺患者的PSADR和PSAPDR,并分别分析在使用阿比特龙和使用比卡鲁胺患者中检出AR-V7与未检出AR-V7的PSADR和PSAPDR。结果AR-V7检出组(30例,52.63%)和未检出组(27例,47.37%)在治疗后3个月时的中位PSADR[1.91(0.69,4.56)vs 3.27(1.65,7.22),P=0.042]和中位PSAPDR[1.08%(1.02%,1.11%)vs 1.10%(1.08%,1.14%),P=0.013],差异都具有统计学意义。但在6个月时两组患者中位PSADR[0.99(0.40,2.44)vs 1.69(0.77,3.61),P=0.053]和平均PSAPDR[(0.56±0.02)%vs(0.55±0.02)%,P=0.432]的差异均无统计学意义。亚组分析中,所有结果差异也均无统计学意义。结论新诊断的mHSPC患者中检测出AR-V7的患者在ADT后3个月时具有更差的PSA下降速率和PSA百分比下降速率。
Objective To evaluate the relationship between peripheral blood AR-V7 expression levels and kinetic parameters of PSA after androgen deprivation therapy(ADT)in patients with metastatic hormone sensitive prostate cancer(mHSPC).Methods 57 patients with newly diagnosed mHSPC from June,2020 to October,2021 in our hospital were selected and treated with ADT after peripheral blood AR-V7 testing.Patients were divided into the AR-V7 detected and undetected groups based on the results of AR-V7 testing,and their PSA decline rate(PSADR)and PSA percentage decline rate(PSAPDR)at 3 and 6 months after the treatment were analyzed.In addition,these samples were sub-analyzed.PSADR and PSAPDR of patients using abiraterone and patients using bicalutamide were analyzed in the detected and undetected groups,respectively.In addition,PSADR and PSAPDR in the detected AR-V7 group versus the undetected AR-V7 group were analyzed separately in patients on abiraterone and those on bicalutamide.Results The median PSADR[1.91(0.69,4.56)vs.3.27(1.65,7.22),P=0.042]and median PSAPDR[1.08%(1.02%,1.11%)vs 1.10%(1.08%,1.14%),P=0.013]at 3 months post-treatment were significantly different between the AR-V7 detected group(30,52.63%)and the undetected group(27,47.37%).However,the differences in median PSADR[0.99(0.40,2.44)vs.1.69(0.77,3.61),P=0.053]and mean PSAPDR[(0.56±0.02)%vs(0.55±0.02)%,P=0.432]between the two groups at 6 months were not statistically significant.All results were also not statistically significant in sub-group analysis.Conclusion Patients with newly diagnosed mHSPC in whom AR-V7 detected show a worse rate of PSA decline and percent PSA decline at 3 months post ADT.
作者
王自勇
毕颖
吴汶钊
吴弘毅
张崇剑
江海洋
胡辰
李俊
白宇
李瑞乾
杨宏
王启林
WANG Ziyong;BI Ying;WU Wenzhao;WU Hongyi;ZHANG Chongjian;JIANG Haiyang;HU Chen;LI Jun;BAI Yu;LI Ruiqian;YANG Hong;WANG Qilin(Yunnan Cancer Hospital(The Third Affiliated Hospital of Kunming Medical University),Kunming 650118,China)
出处
《标记免疫分析与临床》
CAS
2022年第10期1658-1664,共7页
Labeled Immunoassays and Clinical Medicine
基金
国家癌症中心攀登基金(编号:NCC201825B76)。
